Literature DB >> 1761077

Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity.

H Kraul1, J Truckenbrodt, A Huster, R Töpfer, A Hoffmann.   

Abstract

The activity of 7-ethoxycoumarin O-deethylase (ECOD) has been measured in liver biopsy samples from 23 patients (smokers and non-smokers) with different degrees of structural liver damage. The results, which reflect in vitro cytochrome P450-dependent biotransformation, were correlated with various measures of the P450-dependent in vivo elimination of caffeine and metamizol. The relatively non-specific, low affinity component of ECOD activity was significantly correlated with the kinetics of metamizol (mean residence time, apparent clearance, half-life, area under the concentration-time curve, and metabolite excretion in the urine). Thus, metamizol elimination, which is mainly due to P450 IIB, and the low affinity component of ECOD both reflect, at least in part, the activity of the same form of P450. In contrast, caffeine biotransformation, which is via P450 IA, was not correlated with ECOD activity. There was no relation between the kinetics of metamizol and caffeine, perhaps because of the inducing effect that smoking has on caffeine elimination. In patients with liver disease, smoking appears to alter the elimination of caffeine more than the degree of liver disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1761077     DOI: 10.1007/BF00626373

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  29 in total

1.  Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis.

Authors:  R Joeres; H Klinker; H Heusler; J Epping; W Zilly; E Richter
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

2.  Aminopyrine demethylase. Kinetic evidence for multiple microsomal activities.

Authors:  T C Pederson; S D Aust
Journal:  Biochem Pharmacol       Date:  1970-07       Impact factor: 5.858

3.  [Caffeine in chronic liver diseases].

Authors:  W Zilly; U Caesar; E Richter; H Heusler
Journal:  Dtsch Med Wochenschr       Date:  1983-03-25       Impact factor: 0.628

4.  Monooxygenase enzyme activity in alcoholics with varying degrees of liver damage.

Authors:  H Hoensch; F Hartmann; H Schomerus; P Bieck; W Dölle
Journal:  Gut       Date:  1979-08       Impact factor: 23.059

5.  Methylcholanthrene but not phenobarbital enhances caffeine and theophylline metabolism in cultured adult human hepatocytes.

Authors:  D Ratanasavanh; F Berthou; Y Dreano; P Mondine; A Guillouzo; C Riche
Journal:  Biochem Pharmacol       Date:  1990-01-01       Impact factor: 5.858

6.  Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes.

Authors:  M E Campbell; D M Grant; T Inaba; W Kalow
Journal:  Drug Metab Dispos       Date:  1987 Mar-Apr       Impact factor: 3.922

7.  Aminopyrine metabolism by multiple forms of cytochrome P-450 from rat liver microsomes: simultaneous quantitation of four aminopyrine metabolites by high-performance liquid chromatography.

Authors:  S Imaoka; K Inoue; Y Funae
Journal:  Arch Biochem Biophys       Date:  1988-08-15       Impact factor: 4.013

8.  The effect of alcoholic cirrhosis on the activities of microsomal aldrin epoxidase, 7-ethoxycoumarin O-de-ethylase and epoxide hydrolase, and on the concentrations of reduced glutathione in human liver.

Authors:  K W Woodhouse; F M Williams; E Mutch; P Wright; O F James; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

9.  The effect of alcoholic cirrhosis on the two kinetic components (high and low affinity) of the microsomal 0-deethylation of 7-ethoxycoumarin in human liver.

Authors:  K W Woodhouse; F M Williams; E Mutch; P Wright; O F James; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Fibrotic process and drug metabolism in alcoholic liver disease.

Authors:  E A Sotaniemi; O Niemelä; L Risteli; F Stenbäck; R O Pelkonen; J T Lahtela; J Risteli
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

View more
  7 in total

Review 1.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 2.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.

Authors:  Urs Duthaler; Fabio Bachmann; Claudia Suenderhauf; Tanja Grandinetti; Florian Pfefferkorn; Manuel Haschke; Petr Hruz; Jamal Bouitbir; Stephan Krähenbühl
Journal:  Clin Pharmacokinet       Date:  2022-05-16       Impact factor: 5.577

Review 4.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

5.  Evidence for concurrent effects of exposure to environmental cadmium and lead on hepatic CYP2A6 phenotype and renal function biomarkers in nonsmokers.

Authors:  Soisungwan Satarug; Muneko Nishijo; Pailin Ujjin; Yuvaree Vanavanitkun; Jason R Baker; Michael R Moore
Journal:  Environ Health Perspect       Date:  2004-11       Impact factor: 9.031

6.  CREBH determines the severity of sulpyrine-induced fatal shock.

Authors:  Naganori Kamiyama; Masahiro Yamamoto; Hiroyuki Saiga; Ji Su Ma; Jun Ohshima; Sakaaki Machimura; Miwa Sasai; Taishi Kimura; Yoshiyasu Ueda; Hisako Kayama; Kiyoshi Takeda
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

Review 7.  Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.

Authors:  M Teresa Donato; José V Castell
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.